Key Highlights

  • Moderna traded around USD 193.62 on October 23, 2026, about 4% below the prior session.
  • Thursday's loss ranged between 17.6% and 25%, depending on timing and the measure used.
  • By early October, the shares had gained nearly 600% for the year.
  • The combination lowered recurrence or death risk, but the benefit missed the most optimistic expectations.

Why Did Positive Melanoma Data Fail to Halt Moderna's 4% Slide?

Moderna (NASDAQ:MRNA) remained under pressure because an apparently early release of Phase 3 melanoma findings delivered a smaller benefit than the market's most optimistic assumptions. The stock traded at USD 193.62 during the morning of Friday, October 23, 2026, down roughly 4% after Thursday's loss had measured between 17.6% and 25%, depending on the selected measure and point in the day.

Merck (NYSE:MRK) and Moderna developed the patient-specific intismeran autogene vaccine and tested it with Keytruda. The comparison group received Keytruda by itself. Recurrence or death became less likely with the combination, though the improvement was smaller than the most bullish forecasts and the outcome of a previous, smaller study in another population. Merck eased 0.8% to about USD 146, and Pfizer (NYSE:PFE) lost 0.7% to USD 30.22.

How Did a Nearly 600% Rally Raise the Bar for Success?

Expectations explain why favourable findings coincided with selling. The Phase 3 programme reached its primary objective on Wednesday, August 19, 2026. A subsequent rally left Moderna ahead almost 600% for the year by early October, embedding assumptions of a large effect and broad cancer use.

A successful result with a narrower incremental benefit can reduce peak-sales forecasts. Physicians and payers must decide whether an individually manufactured, costly vaccine provides enough additional value on top of Keytruda. The apparent leak also displaced the planned conference disclosure and forced investors to adjust positions without an orderly presentation.

Sentiment had already shown strain. On Thursday, October 1, 2026, Citigroup changed its recommendation to Sell, several weeks before the findings appeared.

The clinical and market outcomes answer different questions. Meeting the study objective establishes that a treatment worked under the protocol. It does not determine whether the effect is large enough to justify commercial assumptions embedded after a sixfold annual advance. Friday's continuation lower reflected that valuation question.

Which Disclosure, Cost and Volatility Risks Remain?

The full presentation could confirm only a modest incremental effect, maintaining pressure on revenue models. Detailed survival curves and patient subgroups from the ESMO congress in Madrid are therefore central to the debate.

Manufacturing introduces another concern because every personalised dose must be produced for an individual patient. That requirement influences margins and adoption speed. Price volatility is also elevated after a gain near 600%, since momentum holders can leave rapidly when a major event disappoints.

The wider biotechnology group was little changed while the named peers slipped, making expectations around the vaccine the primary issue rather than a uniform sector selloff. Trial evidence does not ensure approval or commercial demand.

What to Watch Next: Will October 26 and 29 Events Reshape the Vaccine Thesis?

Trading on Monday, October 26 will provide the first response after the complete ESMO presentation. Merck reports before Thursday's open on October 29, and either partner could provide a regulatory filing schedule.

Those updates will determine whether Friday's level near USD 194 and the earlier 17.6% to 25% decline fully reflect the more measured benefit. The result remains clinically positive, but the valuation had demanded more. Readers should not treat this material as investment advice.